Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00065442 · ClinicalTrials.gov registry record · Phase 3
Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
A Phase 3 study, sponsored by Dendreon.
- Completed
- Registry status
- Phase 3
- Development phase
- 512
- Enrollment target
NCT00065442 is a Phase 3 study that has completed, run by Dendreon. The registered enrollment target is 512 participants.
The verdict
NCT00065442, a Phase 3 study, has completed, sponsored by Dendreon.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 512 participants
- Enrollment target
Study Summary
Provenge is an investigational product designed to activate a man's own antigen presenting cells, a type of immune cell, so that they can detect prostate cancer cells and initiate an immune response against them. Having completed Phase 1 and Phase 2 clinical trials, Provenge is now at the Phase 3 level. One important Phase 3 trial of Provenge has been completed; the current trial is also a Phase 3 study. If you decide to participate and are eligible, you will be enrolled in the study and randomly assigned to receive either active product or placebo. There are two chances in three that you will receive Provenge. After receiving treatment, you will be monitored at regular intervals until the study endpoints are met. At the end of the trial, men who received placebo will have the opportunity to be treated with active product in another study.
Interventions
- BIOLOGICAL Sipuleucel-T
- BIOLOGICAL APC-Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 512 participants |
| Start Date | 2003-07 |
| Est. Completion | 2009-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00065442
The ClinicalTrials.gov registry entry for NCT00065442 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 512 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dendreon, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sipuleucel-T is the first listed.
NCT00065442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00065442 about?
NCT00065442 is a clinical study titled "Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy". Provenge is an investigational product designed to activate a man's own antigen presenting cells, a type of immune cell, so that they can detect prostate cancer cells and initiate an immune response against them. Having completed Phase 1 and Phase 2 clinical trials, Provenge is now at the Phase 3 l...
What is the current status of trial NCT00065442?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 512 participants. The study started on 2003-07. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00065442?
The interventions under investigation include: Sipuleucel-T (BIOLOGICAL), APC-Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT00065442?
This trial is sponsored by Dendreon, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.